HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
HeartBeam has joined the EU-funded EXIT-CVD research consortium alongside Philips, Medtronic, GE HealthCare and other global healthcare leaders, and will lead the HEART-CHECK study, one of the project's 22 clinical studies. HEART-CHECK will evaluate whether HeartBeam's at-home 3D ECG System can help clinicians detect recurrent cardiac events earlier in patients recently discharged after an acute coronary syndrome. HeartBeam's contribution is in-kind, and the System is not CE marked and is investigational in this setting.
Key figures
- Countries
- 17
- Clinical studies
- 22
- Patients enrolled
- more than 14,000
- Project budget eur
- EUR 27.6 million
- Consortium partners
- 42
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.